BIOINVENT INTERNATIONAL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.1 SEK | -0.95% |
|
-0.95% | +37.66% |
| May. 03 | Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member | CI |
| Apr. 30 | BioInvent Announces Evaluating Attana Technology | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 63.6M 5.84M | Sales 2025 * | 1.2B 110M | Capitalization | 1.73B 159M |
|---|---|---|---|---|---|
| Net income 2024 * | -417M -38.3M | Net income 2025 * | 511M 46.93M | EV / Sales 2024 * | 22.2 x |
| Net cash position 2024 * | 320M 29.34M | Net cash position 2025 * | 1.49B 137M | EV / Sales 2025 * | 0.2 x |
| P/E ratio 2024 * |
-6.71
x | P/E ratio 2025 * |
2.71
x | Employees | 109 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioInvent International AB
More press releases
| 1 day | -1.80% | ||
| 1 week | -0.95% | ||
| Current month | +0.38% | ||
| 1 month | +39.57% | ||
| 3 months | +62.72% | ||
| 6 months | +72.39% | ||
| Current year | +37.66% |
1 week
25.75
28.45
1 month
17.9828.45
Current year
15.0028.45
1 year
14.0029.40
3 years
14.0061.40
5 years
14.0063.00
10 years
14.00106.00
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Welschof
CEO | Chief Executive Officer | 63 | 18-08-31 |
Stefan Ericsson
DFI | Director of Finance/CFO | 61 | 97-12-31 |
Marie Moores
COO | Chief Operating Officer | - | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 17-12-31 |
Leonard Kruimer
CHM | Chairman | 66 | 16-05-11 |
Vincent Ossipow
BRD | Director/Board Member | 55 | 16-05-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 26.1 | -0.95% | 32 124 |
| 24-05-07 | 26.35 | -2.41% | 107,811 |
| 24-05-06 | 27 | +0.19% | 79,938 |
| 24-05-03 | 26.95 | +2.28% | 80,527 |
| 24-05-02 | 26.35 | +1.35% | 251,527 |
Delayed Quote Nasdaq Stockholm, May 08, 2024 at 06:59 am EDT
More quotes
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
2024-05-11
- Bio Equity Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
26.35
SEK
Average target price
83
SEK
Spread / Average Target
+214.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.66% | 160M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +8.15% | 23.47B | |
| -13.89% | 21.9B | |
| -6.17% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- BINV Stock